Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

BACKGROUND: The standard treatment for patients with unresectable locally advanced (LA) non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukui, Tomoya, Hosotani, Shinji, Soda, Itaru, Ozawa, Takahiro, Kusuhara, Seiichiro, Kakegawa, Mikiko I., Kasajima, Masashi, Hiyoshi, Yasuhiro, Igawa, Satoshi, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Ishiyama, Hiromichi, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113036/
https://www.ncbi.nlm.nih.gov/pubmed/32057187
http://dx.doi.org/10.1111/1759-7714.13357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113036/
https://www.ncbi.nlm.nih.gov/pubmed/32057187
http://dx.doi.org/10.1111/1759-7714.13357

Ejemplares similares